Remove Cardiovascular Disease Remove Lipid disorders Remove Outcomes
article thumbnail

Cholesterol’s Star Role in Dementia Prevention: New Insights from the 2024 Lancet Dementia Report 

Cardiometabolic Health Congress

Dyslipidemia, characterized by an imbalance in lipids such as cholesterol, LDL-C, triglycerides, and HDL, can result from various factors, including diet, tobacco and alcohol use, a sedentary lifestyle, or genetic conditions like familial hypercholesterolemia.

article thumbnail

Creative Alliances in Cardiorenal Metabolic Management: A Game Changer (Part 1) 

Cardiometabolic Health Congress

Cardiometabolic risk encompasses a complex spectrum of interrelated conditions, including cardiovascular disease, type 2 diabetes, and metabolic syndrome. This blog post explores the development of such partnerships and their potential to transform healthcare outcomes.

article thumbnail

FDA Approves Wegovy for Cardiovascular Risk Reduction in Adults with Known Heart Disease and Overweight or Obesity

DAIC

The FDA decision is based on the results of the landmark SELECT phase 3 cardiovascular outcomes trial that examined the effect of adding Wegovy 2.4 mg or placebo to cardiovascular standard of care in adults with overweight and obesity with established CVD and without diabetes. 1,2 The primary composite outcome occurred in 6.5%

Obesity 111